Buy Rystiggo (rozanolixizumab-noli)

What is Rystiggo (rozanolixizumab-noli) for?

Rystiggo (rozanolixizumab-noli) is a prescription medicine for adult patients with generalized myashtenia gravis (gMG) who are acetylcholine receptor (anti-AChR) antibody positive or muscle-specific tyrosine kinase (anti-MuSK) antibody positive ^[1].

Rystiggo (rozanolixizumab-noli) is available as an injection (280 mg/2 mL) for subcutaneous administration ^[1].

How does Rystiggo (rozanolixizumab-noli) work?

In gMG, antibodies like anti-AChR and anti-MuSK can disrupt the communication between nerves and certain muscle receptors, leading to muscle weakness, breathing difficulties, fatigue, and other symptoms.

The immune system protein, FcRn, plays a role in prolonging the lifespan of these detrimental antibodies in the body. Rystiggo targets FcRn, inhibiting its ability to preserve these harmful antibodies. As a result, there are fewer antibodies disrupting nerve signaling at the neuromuscular junction ^[3].

Where has Rystiggo (rozanolixizumab-noli) been approved?

In June 2023, Rystiggo (rozanolixizumab-noli) received the FDA’s approval in the USA ^[2]. The medicine is currently being reviewed for approval by the EMA and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Responses from these agencies are expected in the first half of 2024.

References:

1. HIGHLIGHTS OF PRESCRIBING INFORMATION. UCB-USA.com, Accessed 25 September 2023.
2. UCB announces U.S. FDA approval of RYSTIGGO[®] (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis. UCB, 11 July 2023.
3. How RYSTIGGO® Targeted Treatment Works. Rystiggo, Accessed 25 September 2023.